540 related articles for article (PubMed ID: 27121689)
1. Radium-223 dichloride in clinical practice: a review.
Florimonte L; Dellavedova L; Maffioli LS
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
[TBL] [Abstract][Full Text] [Related]
2. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
Morgan SC
J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
[TBL] [Abstract][Full Text] [Related]
3. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium.
Rubini G; Nicoletti A; Rubini D; Asabella AN
Cancer Biother Radiopharm; 2014 Feb; 29(1):1-11. PubMed ID: 24180669
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
5. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
6. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
Blacksburg SR; Witten MR; Haas JA
Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
[TBL] [Abstract][Full Text] [Related]
7. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
Nilsson S
Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
[TBL] [Abstract][Full Text] [Related]
8. [Targeted radionuclide therapy for castration-resistant prostate cancer].
Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
[TBL] [Abstract][Full Text] [Related]
9. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
10. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
[TBL] [Abstract][Full Text] [Related]
11. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
[TBL] [Abstract][Full Text] [Related]
12. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Pierce W; Maher VE; Zhang H; Tang S; Song P; Liu Q; Haber MT; Leutzinger EE; Al-Hakim A; Chen W; Palmby T; Alebachew E; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2014 Jan; 20(1):9-14. PubMed ID: 24190979
[TBL] [Abstract][Full Text] [Related]
13. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
Heinzer H; König F; Klutmann S
Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
[TBL] [Abstract][Full Text] [Related]
14. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
15. Practical guide to the use of radium 223 dichloride.
Den RB; Doyle LA; Knudsen KE
Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
17. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 in metastatic castration resistant prostate cancer.
Vuong W; Sartor O; Pal SK
Asian J Androl; 2014; 16(3):348-53. PubMed ID: 24713838
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
[TBL] [Abstract][Full Text] [Related]
20. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Miranda J; Viñal D; Pinto Á
Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]